Prognostic biomarker HAMP and associates with immune infiltration in gastric cancer

Background: Gastric cancer remains one of the most common malignant tumors and has high morbidity and mortality rates. Hepcidin, as a peptide hormone, plays a vital role in regulating systemic iron homeostasis. Nevertheless, the clinical predictive value of HAMP, especially its correlation with immune cell infiltration in gastric cancer, has not yet been elucidated. Methods: HAMP expression in gastric cancer cells and tissues was assessed using experiments and bioinformatics platforms. Clinical and pathologic information was collected to stratify patients with gastric cancer for comparison. We used Kaplan-Meier and Cox regression methods to explore the association between HAMP expression levels and overall survival. Based on The Cancer Genome Atlas datasets, we analyzed whether HAMP expression is associated with immune cell infiltration levels and evaluated the prognostic impact of HAMP on survival of patients with gastric cancer partially through immune cell infiltration. Results: HAMP mRNA was more highly expressed in gastric cancer cells and tumor tissues than in normal tissues. Moreover, elevated HAMP expression was correlated with poor overall survival. In addition, HAMP expression was related to sex, tumor stage, node stage, metastasis stage, Lauren classification, and differentiation in stratified patients. Notably, HAMP gene expression was found to be significantly related to the infiltration levels of immune cells, and that HAMP affects the survival rate in gastric cancer through the immune pathway. Conclusion: High HAMP expression may serve as an independent prognostic biomarker through the immune pathway in patients with gastric cancer.

Automated summary

This study found that high expression of HAMP is associated with poor prognosis in gastric cancer, and HAMP affects the survival rate of patients with gastric cancer through immune cell infiltration.